© Reuters. The Pfizer logo is seen at their world headquarters in New York MUMBAI (Reuters) - India has again denied Inc (NYSE:PFE) a patent on its rheumatoid arthritis drug tofacitinib, the latest setback for a multinational drugmaker seeking to enforce its intellectual property rights in the country. Pfizer sought a patent that covers an important chemical formulation of the active compound in the medicine, but the Indian Patent Office said the company would have to establish that the... More